Physician profile
Robert C Teltser
NPI 1821291675
$5,638.43
in general payments reported to CMS, 2019-2025
36 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $659 · 2021: $1,017 · 2022: $524 · 2023: $1,000 · 2024: $595 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $818.25 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $678.21 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $642.00 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $592.56 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $470.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.64 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $231.82 | 2023-2025 | Mounjaro, Jardiance, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $188.59 | 2020-2022 | |
| Allergan, INC. | $180.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $163.86 | 2019-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $155.47 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.38 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $135.02 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bausch Health US, LLC | $84.40 | 2021-2025 | Aplenzin, Wellbutrin |
| Arbor Pharmaceuticals, INC. | $79.53 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $75.80 | 2019-2020 | |
| Astellas Pharma US INC | $73.53 | 2019-2024 | Veozah |
| Esperion Therapeutics, INC. | $69.50 | 2021 | |
| Eisai INC. | $47.07 | 2021 | |
| Seqirus USA INC | $40.51 | 2019-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Biomerieux INC | $38.71 | 2025 | Biofire Spotfire Control Station |
| Zyla Life Sciences, INC. | $36.69 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.37 | 2023 | Eliquis |
| Medtronic Vascular, INC. | $32.63 | 2019 | |
| Exact Sciences Corporation | $32.41 | 2023 | Cologuard Collection Kit |
| Vivus LLC | $31.98 | 2019 | |
| Mayne Pharma Commercial LLC | $31.93 | 2023 | |
| Sumitomo Pharma America, INC. | $29.48 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $28.49 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $24.51 | 2019 | |
| Kaleo, INC. | $23.94 | 2021 | |
| Endo Pharmaceuticals INC. | $22.13 | 2020 | |
| Ironwood Pharmaceuticals, INC | $19.86 | 2019 | |
| Intra-Sana Laboratories | $18.95 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Teva Pharmaceuticals USA, INC. | $18.56 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Teltser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.